View ValuationPathkey.AI 将来の成長Future 基準チェック /06現在、 Pathkey.AIの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Software 収益成長27.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Shannon Robinson was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Shannon Robinson was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 04Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million.Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 188,549,547 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Subsequent Direct Listingお知らせ • Jan 07Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million.Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,981,343 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Rights OfferingBoard Change • Dec 31No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Dec 17Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million.Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 188,549,547 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Subsequent Direct Listingお知らせ • Nov 27Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,783,786 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 188,549,547 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Subsequent Direct Listingお知らせ • Oct 02Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025.New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.3m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$268k). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (AU$322k revenue, or US$211k). Market cap is less than US$10m (AU$7.10m market cap, or US$4.65m).Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.008 loss per share (vs AU$0.018 loss in FY 2024)Full year 2025 results: AU$0.008 loss per share (improved from AU$0.018 loss in FY 2024). Net loss: AU$1.45m (loss narrowed 54% from FY 2024). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Board Change • Aug 18No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • May 02Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,000,000 Price\Range: AUD 0.021 Discount Per Security: AUD 0.00126 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: AUD 0.021 Discount Per Security: AUD 0.00126 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 11Opyl Limited, Annual General Meeting, Nov 21, 2024Opyl Limited, Annual General Meeting, Nov 21, 2024.お知らせ • Sep 05Opyl Limited Announces Company Secretary ChangesOpyl Limited announced the appointment of Mr. Jonathan Hart as the new Company Secretary, effective immediately. Mr. Hart has 20+ years of corporate advisory experience. He has extensive cross border experience specializing in corporate advisory, scale up and debt and equity financing, across a broad range of industry sectors. Mr. Hart holds a Bachelor of Laws and Commerce and currently serves as a director of Hartness Consulting Pty Ltd, established in 2012 specializing in corporate advisory and equity services to private and publicly listed companies in a range of sectors including technology, healthcare and resources. His extensive experience and deep understanding of corporate governance, compliance, and strategic advisory will be instrumental as Opyl continues to execute its strategic initiatives. The Board takes this opportunity to thank Mr. David Lilja of DLK Advisory for his invaluable contributions to the Company as the outgoing Company Secretary.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.018 loss per share (vs AU$0.022 loss in FY 2023)Full year 2024 results: AU$0.018 loss per share. Revenue: AU$932.1k (up 51% from FY 2023). Net loss: AU$3.13m (loss widened 81% from FY 2023).お知らせ • Aug 23Opyl Limited announced that it has received AUD 0.7 million in fundingOpyl Limited announced that it has received AUD 700,000 through short-term loan agreements in funding on August 22, 2024. The transaction includes participation from new lenders Peak Asset Management LLC, Irwin Biotech Nominees Pty Ltd, Rip Opportunities Pty Ltd and Antanas "Tony" Guoga.お知らせ • Apr 30Opyl Limited, Annual General Meeting, May 27, 2024Opyl Limited, Annual General Meeting, May 27, 2024, at 15:00 E. Australia Standard Time. Agenda: To consider approval of disposal of OPIN business; to election of executive-director Mr. Saurabh Jain; to approval of issue of shares to Mr. Mark Ziirsen conversion of director fees outstanding; to approval of issue of shares to Mr. Damon Rasheed conversion of director fees outstanding; to approval of issue of shares to Mr. Antanas Guoga conversion of director fees outstanding; to approval to issue of 10,000,000 lead manager options; to ratification of prior issue of 19,200,000 placement shares; to ratification of prior issue of 429,185 shares; and to consider other matters if any.Board Change • Mar 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 17Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million.Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,905,260 Price\Range: AUD 0.03 Discount Per Security: AUD 0.0018 Transaction Features: Rights OfferingBoard Change • Jan 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 14+ 1 more updateOpyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.576 million.Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.576 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,199,995 Price\Range: AUD 0.03 Discount Per Security: AUD 0.0018 Transaction Features: Subsequent Direct Listingお知らせ • Nov 24Opyl Limited Appoints Saurabh Jain as Interim Chief Executive OfficerOpyl Limited announced the appointment of Mr. Saurabh Jain as interim Chief Executive Officer of Opyl, effective 24 November 2023. Saurabh is tasked with overseeing and driving the launch of Opyl's new predictive analytics and insights platform, TrialKey, and continuing to support the Opin business as it executes on its new go-to-market strategy. Saurabh is an accomplished technology entrepreneur with a track record of commercialising, scaling and transitioning management to proven leadership in emerging technology businesses. In 1997, he founded Netpro Express, an internet service provider that was later acquired by Telstra. Since then, Saurabh has held various senior executive roles at Ventia, Cushman Wakefield and was previously CEO and Executive Director of Urbanise. Most recently, Saurabh joined the Spacetalk board where he stepped into the role of acting CEO before transitioning to the current leadership, at which point he stepped back into his prior role as Non-Executive Director. Saurabh brings over 25 years of experience across both ASX boards and private companies, leveraging his entrepreneurial and commercial acumen, a history of deep technical expertise and oversight over transformative organisational change. His experience will be critical in accelerating the commercialisation of TrialKey, overseeing the growth of Opin, and driving equity value uplift across the business. Saurabh holds a Bachelor of Engineering (Software Engineering), an Executive Master of Business Administration and a Master of Business Technology from the Australian Graduate School of Management, UNSW.Board Change • Nov 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 31Opyl Limited, Annual General Meeting, Nov 29, 2023Opyl Limited, Annual General Meeting, Nov 29, 2023, at 15:00 AUS Eastern Standard Time. Location: Engine House, 105 Wellington Street Saint Kilda Victoria Australia Agenda: To receive the Financial Statements, Director's Report and Auditor's Report for the Company for the year ended 30 June 2023; to consider and approve the remuneration report; to consider and approve the election of Director; to consider and approve to issue of incentive options; to consider and approve the conversion of Director fees; to consider and approve to issue loan options; and to consider and approve the 10% placement capacity.お知らせ • Aug 24+ 1 more updateOpyl Limited to Report Fiscal Year 2023 Results on Aug 30, 2023Opyl Limited announced that they will report fiscal year 2023 results on Aug 30, 2023New Risk • Jul 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$886k free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m (AU$901k revenue, or US$603k). Market cap is less than US$10m (AU$3.66m market cap, or US$2.45m).お知らせ • Jul 06+ 1 more updateOpyl Limited Announces Senior Leadership ChangesOpyl Limited announced changes to its senior leadership with Dr Hugo Stephenson joining to lead Opin, Michelle Gallaher moving to General Manager of TrialKey and Mark Ziirsen stepping in as the Executive Chairman. These changes follow the Board-led strategic review focused on identifying pathways for accelerating the growth of Opin and developing pathways to commercialise TrialKey. To better support and drive its strategic priorities, the Board announced a realignment of internal resources. As a result, Michelle Gallaher has permanently stepped down as CEO of Opyl Limited, with immediate effect, and will transition to the role of GM TrialKey for a specified period. In her new role, Michelle will work alongside Executive Director and CTO, Damon Rasheed, on further development of the TrialKey platform. The Board is delighted to announce that following his recent appointment as Strategic Advisor to the Board, Dr Hugo Stephenson has agreed to join the company to lead Opin, the company's clinical trial recruitment business. In this role, Dr Stephenson will specifically focus on: Accelerating recruitment for ANZ-based clinical trials and health programs; Streamlining Opin's business model to align with ANZ client needs; Unlocking new business opportunities in patient community growth and management; Broadening Asia Pacific partnerships with research sites, healthcare institutions and advocacy groups; Pursuing M&A opportunities in the Asia Pacific region; and Cultivating global growth opportunities. For the near term, Mr. Mark Ziirsen, Executive Chair will assume expanded executive duties, spending more time in the Melbourne head office, to provide support for these management changes.Board Change • Jun 28No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Jun 05No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • May 04Opyl Limited Appoints Dr. Hugo Stephenson as Board AdvisorOpyl Limited announced that it has engaged leading global clinical trial expert and eminent business leader in the health technology sector, Dr. Hugo Stephenson, as an advisor to the board. His appointment is an important development in the Company's strategic review, which focuses on accelerating the growth of Opin and monetising the TrialKey technology platform. Dr. Stephenson is a medical doctor, technologist, biotech services entrepreneur and founder of a number of successful businesses in the international clinical trials industry, including: DrugDev, a leading provider of e-clinical technologies and clinical trial payment services; MediGuard, the largest online medication monitoring service; Health Research Solutions (HRS), a late phase contract research organisation; and MedSeed, a pioneer of hospital and GP decision support software. Dr. Stephenson worked for many years as the founder of Quintiles' global late phase research division (now IQVIA) following the acquisition of HRS, and has considerable experience managing organisations within both a public market and private equity-backed environment. He is also the founder and past Chief Executive Officer of the Induction Healthcare Group PLC.Board Change • May 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Megan Robertson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pathkey.AI は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:PKY - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-1-1-1N/A9/30/20250-1-1-1N/A6/30/20250-1-1-1N/A3/31/20251-2-2-2N/A12/31/20241-3-2-2N/A9/30/20241-3-2-2N/A6/30/20241-3-2-2N/A3/31/20241-3-2-2N/A12/31/20231-2-2-2N/A9/30/20231-2-1-1N/A6/30/20231-2-1-1N/A3/31/20231-1-1-1N/A12/31/20221-1-1-1N/A9/30/20221-2-1-1N/A6/30/20221-2-2-2N/A3/31/20221-2-2-2N/A12/31/20211-3-2-2N/A9/30/20211-2-1-1N/A6/30/20211-1-1-1N/A3/31/20211-1-1-1N/A12/31/20201000N/A9/30/202010-1-1N/A6/30/20201-1-1-1N/A3/31/20201-2-1-1N/A12/31/20191-3-2-2N/A9/30/20191-3N/A-2N/A6/30/20191-3N/A-2N/A3/31/20191-3N/A-2N/A12/31/20181-3N/A-3N/A9/30/20181-3N/A-3N/A6/30/20180-3N/A-3N/A3/31/20180-3N/A-3N/A12/31/20170-3N/A-2N/A9/30/20170-3N/A-3N/A6/30/20170-3N/A-3N/A3/31/20170-5N/A-4N/A12/31/20160-7N/A-4N/A9/30/20160-7N/A-4N/A6/30/20160-6N/A-3N/A6/30/20150-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PKYの予測収益成長が 貯蓄率 ( 3.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PKYの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PKYの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PKYの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PKYの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PKYの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 21:03終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pathkey.AI Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Shannon Robinson was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 01No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Shannon Robinson was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 04Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million.Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 188,549,547 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 07Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million.Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,981,343 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Rights Offering
Board Change • Dec 31No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Dec 17Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million.Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 188,549,547 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 27Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,783,786 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 188,549,547 Price\Range: AUD 0.012 Discount Per Security: AUD 0.00072 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 02Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025.
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.3m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$268k). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (AU$322k revenue, or US$211k). Market cap is less than US$10m (AU$7.10m market cap, or US$4.65m).
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.008 loss per share (vs AU$0.018 loss in FY 2024)Full year 2025 results: AU$0.008 loss per share (improved from AU$0.018 loss in FY 2024). Net loss: AU$1.45m (loss narrowed 54% from FY 2024). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Board Change • Aug 18No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • May 02Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 42,000,000 Price\Range: AUD 0.021 Discount Per Security: AUD 0.00126 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: AUD 0.021 Discount Per Security: AUD 0.00126 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 11Opyl Limited, Annual General Meeting, Nov 21, 2024Opyl Limited, Annual General Meeting, Nov 21, 2024.
お知らせ • Sep 05Opyl Limited Announces Company Secretary ChangesOpyl Limited announced the appointment of Mr. Jonathan Hart as the new Company Secretary, effective immediately. Mr. Hart has 20+ years of corporate advisory experience. He has extensive cross border experience specializing in corporate advisory, scale up and debt and equity financing, across a broad range of industry sectors. Mr. Hart holds a Bachelor of Laws and Commerce and currently serves as a director of Hartness Consulting Pty Ltd, established in 2012 specializing in corporate advisory and equity services to private and publicly listed companies in a range of sectors including technology, healthcare and resources. His extensive experience and deep understanding of corporate governance, compliance, and strategic advisory will be instrumental as Opyl continues to execute its strategic initiatives. The Board takes this opportunity to thank Mr. David Lilja of DLK Advisory for his invaluable contributions to the Company as the outgoing Company Secretary.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.018 loss per share (vs AU$0.022 loss in FY 2023)Full year 2024 results: AU$0.018 loss per share. Revenue: AU$932.1k (up 51% from FY 2023). Net loss: AU$3.13m (loss widened 81% from FY 2023).
お知らせ • Aug 23Opyl Limited announced that it has received AUD 0.7 million in fundingOpyl Limited announced that it has received AUD 700,000 through short-term loan agreements in funding on August 22, 2024. The transaction includes participation from new lenders Peak Asset Management LLC, Irwin Biotech Nominees Pty Ltd, Rip Opportunities Pty Ltd and Antanas "Tony" Guoga.
お知らせ • Apr 30Opyl Limited, Annual General Meeting, May 27, 2024Opyl Limited, Annual General Meeting, May 27, 2024, at 15:00 E. Australia Standard Time. Agenda: To consider approval of disposal of OPIN business; to election of executive-director Mr. Saurabh Jain; to approval of issue of shares to Mr. Mark Ziirsen conversion of director fees outstanding; to approval of issue of shares to Mr. Damon Rasheed conversion of director fees outstanding; to approval of issue of shares to Mr. Antanas Guoga conversion of director fees outstanding; to approval to issue of 10,000,000 lead manager options; to ratification of prior issue of 19,200,000 placement shares; to ratification of prior issue of 429,185 shares; and to consider other matters if any.
Board Change • Mar 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 17Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million.Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 22,905,260 Price\Range: AUD 0.03 Discount Per Security: AUD 0.0018 Transaction Features: Rights Offering
Board Change • Jan 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 14+ 1 more updateOpyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.576 million.Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.576 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 19,199,995 Price\Range: AUD 0.03 Discount Per Security: AUD 0.0018 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 24Opyl Limited Appoints Saurabh Jain as Interim Chief Executive OfficerOpyl Limited announced the appointment of Mr. Saurabh Jain as interim Chief Executive Officer of Opyl, effective 24 November 2023. Saurabh is tasked with overseeing and driving the launch of Opyl's new predictive analytics and insights platform, TrialKey, and continuing to support the Opin business as it executes on its new go-to-market strategy. Saurabh is an accomplished technology entrepreneur with a track record of commercialising, scaling and transitioning management to proven leadership in emerging technology businesses. In 1997, he founded Netpro Express, an internet service provider that was later acquired by Telstra. Since then, Saurabh has held various senior executive roles at Ventia, Cushman Wakefield and was previously CEO and Executive Director of Urbanise. Most recently, Saurabh joined the Spacetalk board where he stepped into the role of acting CEO before transitioning to the current leadership, at which point he stepped back into his prior role as Non-Executive Director. Saurabh brings over 25 years of experience across both ASX boards and private companies, leveraging his entrepreneurial and commercial acumen, a history of deep technical expertise and oversight over transformative organisational change. His experience will be critical in accelerating the commercialisation of TrialKey, overseeing the growth of Opin, and driving equity value uplift across the business. Saurabh holds a Bachelor of Engineering (Software Engineering), an Executive Master of Business Administration and a Master of Business Technology from the Australian Graduate School of Management, UNSW.
Board Change • Nov 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 31Opyl Limited, Annual General Meeting, Nov 29, 2023Opyl Limited, Annual General Meeting, Nov 29, 2023, at 15:00 AUS Eastern Standard Time. Location: Engine House, 105 Wellington Street Saint Kilda Victoria Australia Agenda: To receive the Financial Statements, Director's Report and Auditor's Report for the Company for the year ended 30 June 2023; to consider and approve the remuneration report; to consider and approve the election of Director; to consider and approve to issue of incentive options; to consider and approve the conversion of Director fees; to consider and approve to issue loan options; and to consider and approve the 10% placement capacity.
お知らせ • Aug 24+ 1 more updateOpyl Limited to Report Fiscal Year 2023 Results on Aug 30, 2023Opyl Limited announced that they will report fiscal year 2023 results on Aug 30, 2023
New Risk • Jul 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$886k free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m (AU$901k revenue, or US$603k). Market cap is less than US$10m (AU$3.66m market cap, or US$2.45m).
お知らせ • Jul 06+ 1 more updateOpyl Limited Announces Senior Leadership ChangesOpyl Limited announced changes to its senior leadership with Dr Hugo Stephenson joining to lead Opin, Michelle Gallaher moving to General Manager of TrialKey and Mark Ziirsen stepping in as the Executive Chairman. These changes follow the Board-led strategic review focused on identifying pathways for accelerating the growth of Opin and developing pathways to commercialise TrialKey. To better support and drive its strategic priorities, the Board announced a realignment of internal resources. As a result, Michelle Gallaher has permanently stepped down as CEO of Opyl Limited, with immediate effect, and will transition to the role of GM TrialKey for a specified period. In her new role, Michelle will work alongside Executive Director and CTO, Damon Rasheed, on further development of the TrialKey platform. The Board is delighted to announce that following his recent appointment as Strategic Advisor to the Board, Dr Hugo Stephenson has agreed to join the company to lead Opin, the company's clinical trial recruitment business. In this role, Dr Stephenson will specifically focus on: Accelerating recruitment for ANZ-based clinical trials and health programs; Streamlining Opin's business model to align with ANZ client needs; Unlocking new business opportunities in patient community growth and management; Broadening Asia Pacific partnerships with research sites, healthcare institutions and advocacy groups; Pursuing M&A opportunities in the Asia Pacific region; and Cultivating global growth opportunities. For the near term, Mr. Mark Ziirsen, Executive Chair will assume expanded executive duties, spending more time in the Melbourne head office, to provide support for these management changes.
Board Change • Jun 28No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Jun 05No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • May 04Opyl Limited Appoints Dr. Hugo Stephenson as Board AdvisorOpyl Limited announced that it has engaged leading global clinical trial expert and eminent business leader in the health technology sector, Dr. Hugo Stephenson, as an advisor to the board. His appointment is an important development in the Company's strategic review, which focuses on accelerating the growth of Opin and monetising the TrialKey technology platform. Dr. Stephenson is a medical doctor, technologist, biotech services entrepreneur and founder of a number of successful businesses in the international clinical trials industry, including: DrugDev, a leading provider of e-clinical technologies and clinical trial payment services; MediGuard, the largest online medication monitoring service; Health Research Solutions (HRS), a late phase contract research organisation; and MedSeed, a pioneer of hospital and GP decision support software. Dr. Stephenson worked for many years as the founder of Quintiles' global late phase research division (now IQVIA) following the acquisition of HRS, and has considerable experience managing organisations within both a public market and private equity-backed environment. He is also the founder and past Chief Executive Officer of the Induction Healthcare Group PLC.
Board Change • May 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Megan Robertson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.